Subscribe
According to the company, post-hoc time-to-event analysis signals up to 59% risk reduction in rate of vision loss compared to sham treatment at 12 months. The analysis will be presented at the ARVO Annual Meeting from April 23-27 in New Orleans.
Industry leaders react to FDA’s pegcetacoplan approval
Pegcetacoplan approved by FDA for geographic atrophy secondary to AMD
Akari Therapeutics moving toward IND for long-acting PAS-nomacopan for geographic atrophy
Angiogenesis 2023: Visual functional loss in geographic atrophy
Neel Pasricha, MD; Asim V. Farooq, MD; Susana Campos, MD, MPH
Charles C. Wykoff MD, PhD; Diana V. Do, MD; Dante Pieramici, MD, FASRS; Jed H. Assam, MD, MS
John Kitchens, MD; Michael W. Stewart, MD
Carl Danzig, MD, FASRS; Sruthi Arepalli, MD; Priya Vakharia, MD, FASRS
Mile Brujic, OD, FAAO; Pierce Kenworthy, OD, FAAO; Blair Lonsberry, MS, OD, MEd, FAAO
Murtaza K. Adam, MD, FASRS; Deepak Sambhara, MD, FASRS; Betty Zhang, OD